Demographic data and baseline characteristics of randomised patients
| Salmeterol(n = 184) | Salmeterol + fluticasone(n = 189) | |
|---|---|---|
| ICS, inhaled corticosteroids; LABA, long acting β2 agonists; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow; SGRQ, St George’s Respiratory Questionnaire. | ||
| *Mean (SD). | ||
| †Median (range). | ||
| ‡During run-in period. | ||
| Age (years)* | 64.0 (7.7) | 63.0 (7.9) |
| Male | 137 (75%) | 138 (73%) |
| Current smoker | 64 (35%) | 74 (39%) |
| Pack-years smoked* | 37.8 (18.1) | 34.8 (17.4) |
| Previous ICS | 44 (24%) | 39 (21%) |
| Previous LABA | 6 (3%) | 6 (3%) |
| Previous ICS+LABA | 116 (63%) | 120 (64%) |
| Pretreatment FEV1 (l)* | ||
| At start of run-in | 1.44 (0.42) | 1.43 (0.49) |
| At randomisation | 1.41 (0.46) | 1.41 (0.51) |
| Prebronchodilator FEV1, (% predicted)* | ||
| At start of run-in | 49.0 (11.6) | 48.1 (11.6) |
| At randomisation | 48.2 (12.9) | 47.4 (13.9) |
| Reversibility (% predicted FEV1)* | ||
| At start of run-in | 4.3 (3.0) | 4.5 (3.1) |
| At randomisation | 4.9 (4.1) | 4.7 (3.5) |
| FVC (l)* | ||
| At start of run-in | 3.07 (0.84) | 3.12 (0.90) |
| At randomisation | 3.08 (0.88) | 3.10 (0.88) |
| PEF (l/s)* | ||
| At start of run-in | 4.34 (1.42) | 4.24 (1.37) |
| At randomisation | 4.48 (1.40) | 4.36 (1.47) |
| SGRQ total score* | ||
| At start of run-in | 41.9 (16.2) | 40.7 (12.7) |
| At randomisation | 39.6 (15.8) | 38.6 (13.0) |
| Use of relief medication per day†‡ | 0.9 (0–7) | 0.9 (0–8) |
| No of disturbed nights per week†‡ | 2.0 (0–7) | 2.1 (0–7) |